News
Newsletter Signup
Signup to get access to our regular monthly EU Insights newsletter and stay up to date with all the latest from PAREA.
PAREA receives €50,000 grant from Entheon Foundation to advance psychedelic-assisted mental health treatments in Europe
PAREA has received a generous €50,000 grant from the Entheon Foundation, recognising our work to integrate psychedelic-assisted mental health treatments into Europe’s healthcare systems.
New expert commentary outlines five priorities to advance psychedelic therapies in mental health care
A new expert commentary is outlining five priorities to advance psychedelic therapies in mental health care. Published on The Mental Elf—an online resource on mental health research—the piece follows the 2024 IMHRF webinar “Making sense of psychedelics: Where is the field and where does it need to go?”
Europe Invests in the Future of Psychedelic Science: INTEGRATE Doctoral Network Launches with €4.3 Million in Funding
A second major EU-funded project in psychedelic science, following PsyPal, will start in the coming months. INTEGRATE will be a doctoral training network supported by €4.3 million in EU funding through the Marie Skłodowska-Curie Actions.
Welcoming Nico Gusac to the PAREA team
PAREA is delighted to welcome Nico Gusac as our new Communications Officer!
Health4Europe – a Blueprint for Health in the next Long Term EU Budget
Today, the EU4Health Civil Society Alliance launched Health4Europe—a strategic blueprint for the next EU Health Programme. Its goal is to ensure that health remains a top political and financial priority in the upcoming Multiannual Financial Framework (MFF), and to further strengthen the European Health Union.
From Denver to Helsinki: PAREA celebrates its third birthday at the European Academy of Neurology Congress 2025!
Just days after presenting in Denver, the PAREA team travelled to Helsinki to participate in the European Academy of Neurology (EAN) Congress, a major event that also marked PAREA’s three-year anniversary.
Australia’s largest health insurer funds MDMA therapy pilot, calls mental health a national priority
Australia’s largest private health insurer, Medibank, has committed AUD $10 million (~EUR 6 million) to support patient access to MDMA-assisted therapy for PTSD, along with a health economics and outcomes study led by the Australian National University.
PAREA at the REAL Summit in London
Earlier in June, PAREA’s Founder Tadeusz Hawrot participated in the REAL Summit London, a dynamic gathering of changemakers, investors, and innovators committed to transforming global mental health. Hosted by the REAL Mental Health Foundation, the event spotlighted urgent challenges in mental health care—most notably, the persistent stigma that continues to prevent millions from seeking help.
PAREA Participation in Psychedelic Science 2025
PAREA will be present next week at Psychedelic Science 2025, in Denver, Colorado!
PAREA’s response to the EU Biotech Act to Unlock Mental-Health Innovation
PAREA has submitted a response to the European Commission’s open call for evidence on the EU Biotech Act: “Shaping the EU Biotech Act to Unlock Mental-Health Innovation”. We welcome this ambition, which has highlighted mental health as a critical priority.
EUDA drug report highlights trends and developments in psychedelics
The EU Drugs Agency (EUDA) has released its annual European Drug Report, focusing on emerging trends in the European drug market. It includes a chapter on the growing interest in psychedelics for therapeutic use.
Czech Republic opens door to psychedelic therapy for mental health conditions
The Czech Parliament has passed a significant law allowing psilocybin therapy for mental health conditions like depression, anxiety, and addiction.
WHO releases rapid communication on controlled medicines guideline
The World Health Organization (WHO) has issued a rapid communication on its forthcoming guideline on controlled medicines, designed to support national policies that strike a balance between access and safety. PAREA was honoured to be invited to join the External Review Group for this new guideline.
New EU-funded network to support psychedelic research across Europe
A new European research network focused on psychedelics has been approved for funding under the COST (European Cooperation in Science and Technology) programme.
“Leading not Lagging” - PAREA launches policy paper urging Europe to lead on mental health innovation
New PAREA Policy Paper: “Leading, not Lagging: Putting Mental Health at the Core of Europe’s Innovation and Competitiveness Agenda.”
Portugal launches multidisciplinary clinical guidance on psychedelic therapies
On May 12, the Champalimaud Foundation hosted the official launch of Portugal’s Multidisciplinary Recommendations on the Clinical Use of Psychedelic Substances.
Building capacity in crisis: psychedelic-assisted therapy training in Ukraine
From April 28 to May 4, a landmark educational event on psychedelic therapy took place in Lviv, Ukraine, organised by the Multidisciplinary Association for Psychedelic Studies (MAPS) in partnership with the Ukrainian Psychedelic Research Association (UPRA). PAREA Founder & Executive Tadeusz Hawrot joined as an invited observer.
PAREA at Breaking Convention 2025
In April, PAREA Project Officer Francisca Silva took part in Breaking Convention - one of Europe’s largest and most diverse conferences on psychedelic research.
PAREA at the PsyPal workshop in Barcelona
As part of the EU-funded PsyPal project, our Founder and Executive Director, Tadeusz Hawrot, recently participated in a two-day Design Thinking Workshop hosted by IESE Business School in Barcelona.
Welcoming Reconnect Foundation to the PAREA Community
We’d like to extend a warm welcome to Reconnect Foundation, our newest Community Supporter!

